{"id":219916,"date":"2025-08-12T12:06:41","date_gmt":"2025-08-12T17:06:41","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/08\/new-study-demonstrates-improved-survival-with-combination-of-lurbinectedin-and-atezolizumab-for-extensive-stage-small-cell-lung-cancer"},"modified":"2025-08-12T12:06:41","modified_gmt":"2025-08-12T17:06:41","slug":"new-study-demonstrates-improved-survival-with-combination-of-lurbinectedin-and-atezolizumab-for-extensive-stage-small-cell-lung-cancer","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/08\/new-study-demonstrates-improved-survival-with-combination-of-lurbinectedin-and-atezolizumab-for-extensive-stage-small-cell-lung-cancer","title":{"rendered":"New Study Demonstrates Improved Survival With Combination of Lurbinectedin and Atezolizumab for Extensive-Stage Small Cell Lung Cancer"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/new-study-demonstrates-improved-survival-with-combination-of-lurbinectedin-and-atezolizumab-for-extensive-stage-small-cell-lung-cancer2.jpg\"><\/a><\/p>\n<p>\u201cImmunotherapy has improved survival outcomes for patients with extensive-stage small cell lung cancer (ES-SCLC), marking meaningful progress in a historically challenging disease. However, despite these advances, long-term outcomes remain suboptimal, underscoring the need for better strategies. The integration of lurbinectedin\u2014a novel DNA-damaging agent\u2014into the maintenance setting alongside atezolizumab following initial chemo-immunotherapy represents an important next step. This approach offers a way to extend disease control and may signal a shift toward more durable benefit for patients,\u201d said Charu Aggarwal, MD, MPH, FASCO, Leslye M Heisler Professor of Lung Cancer Excellence at University of Pennsylvania \u2013 Abramson Cancer Center, and an ASCO Expert in lung cancer.<\/p>\n<hr>\n<p>\n<em>ALEXANDRIA, Va. <\/em>\u2014 Results from a global phase 3 clinical trial found that maintenance therapy with a combination of lurbinectedin and atezolizumab helped some patients with extensive-stage small cell lung cancer (ES-SCLC) live longer compared to maintenance therapy with atezolizumab alone. The research will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3 in Chicago.<\/p>\n<p><strong>About the Study<\/strong><\/p>\n<p>\u201cWhile the introduction of immunotherapy in first-line treatment has improved outcomes, advanced small cell lung cancer remains difficult to treat. The phase 3 IMforte trial shows that the new treatment combination of lurbinectedin and atezolizumab given as maintenance therapy after first-line treatment helps people live longer and reduces the risk of disease progression or death. This outcome represents a major milestone and could provide a much-needed option for advancing the treatment of this aggressive disease,\u201d said lead study author Luis G. Paz Ares, MD, PhD, 12 de Octubre University Hospital in Madrid, Spain.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u201cImmunotherapy has improved survival outcomes for patients with extensive-stage small cell lung cancer (ES-SCLC), marking meaningful progress in a historically challenging disease. However, despite these advances, long-term outcomes remain suboptimal, underscoring the need for better strategies. The integration of lurbinectedin\u2014a novel DNA-damaging agent\u2014into the maintenance setting alongside atezolizumab following initial chemo-immunotherapy represents an important next [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-219916","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/219916","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=219916"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/219916\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=219916"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=219916"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=219916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}